New drug duo aims to outsmart Hard-to-Treat lymphoma
NCT ID NCT06948786
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 40 times
Summary
This phase 2 trial is testing whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has relapsed or is refractory. Pirtobrutinib blocks a protein that helps cancer cells grow, while mosunetuzumab helps the body's immune T cells attack the cancer. The study will enroll 22 adults with grade 1-3a follicular lymphoma who have already tried at least two prior treatments. Researchers hope this combo improves remission rates and reduces side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib and mosunetuzumab
What this could lead to
If successful, this combination could offer a more effective treatment option for patients with follicular lymphoma that has returned or not responded to prior therapies, potentially with fewer severe side effects.
What could go wrong
This is a small, early-phase trial with only 22 participants, so results may not apply broadly. The combination may not work as hoped, and side effects like cytokine release syndrome remain a risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.